How to buy Kazia Therapeutics stock - 21 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kazia Therapeutics stock

Own Kazia Therapeutics stock in just a few minutes.

Kazia Therapeutics Limited is a biotechnology business based in the US. Kazia Therapeutics shares (KZIA) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Kazia Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KZIA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kazia Therapeutics share price

Use our graph to track the performance of KZIA stocks over time.

Kazia Therapeutics shares at a glance

Information last updated 2021-04-15.
52-week range$2.50 - $15.85
50-day moving average $11.34
200-day moving average $9.37
Wall St. target price$17.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.92

Buy Kazia Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kazia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kazia Therapeutics financials

Revenue TTM $363,489
Gross profit TTM $988,000
Return on assets TTM -26.94%
Return on equity TTM -58.95%
Profit margin 0%
Book value $2.51
Market capitalisation $155.9 million

TTM: trailing 12 months

Shorting Kazia Therapeutics shares

There are currently 27,668 Kazia Therapeutics shares held short by investors – that's known as Kazia Therapeutics's "short interest". This figure is 27.2% down from 37,983 last month.

There are a few different ways that this level of interest in shorting Kazia Therapeutics shares can be evaluated.

Kazia Therapeutics's "short interest ratio" (SIR)

Kazia Therapeutics's "short interest ratio" (SIR) is the quantity of Kazia Therapeutics shares currently shorted divided by the average quantity of Kazia Therapeutics shares traded daily (recently around 138340). Kazia Therapeutics's SIR currently stands at 0.2. In other words for every 100,000 Kazia Therapeutics shares traded daily on the market, roughly 200 shares are currently held short.

However Kazia Therapeutics's short interest can also be evaluated against the total number of Kazia Therapeutics shares, or, against the total number of tradable Kazia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kazia Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kazia Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Kazia Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kazia Therapeutics.

Find out more about how you can short Kazia Therapeutics stock.

Kazia Therapeutics share dividends

We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.

Have Kazia Therapeutics's shares ever split?

Kazia Therapeutics's shares were split on a 1:4 basis on 13 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics's share price.

Kazia Therapeutics share price volatility

Over the last 12 months, Kazia Therapeutics's shares have ranged in value from as little as $2.5 up to $15.85. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kazia Therapeutics's is 2.7913. This would suggest that Kazia Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Kazia Therapeutics overview

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site